Aethlon Medical increases authorized common stock to 200 million shares

Aethlon Medical, Inc. has formally increased its authorized common stock from 20 million to 200 million shares. The company filed an 8-K report with the U.S. Securities and Exchange Commission on October 9, 2026. Stockholders approved the change at the annual meeting held on October 1, 2026.

The filing confirms the Articles Amendment was submitted to the Secretary of State of the State of Nevada. It became effective on October 7, 2026. This action amends Article V of the company's Articles of Incorporation to authorize an aggregate of 200 million shares of common stock, each with a par value of $0.001. The company identified this change under Item 5.03 of the Form 8-K, which covers amendments to articles of incorporation or bylaws.

Aethlon Medical is incorporated in Nevada. Its principal executive offices are at 11555 Sorrento Valley Road, Suite 203, in San Diego, California. The company's common stock, designated by the ticker symbol AEMD, trades on the Nasdaq Capital Market. The 8-K filing includes a certificate of amendment as Exhibit 3.1, which is incorporated by reference into the report.

James B. Frakes, who serves as both Chief Executive Officer and Chief Financial Officer for Aethlon Medical, signed the report on behalf of the registrant. The document notes that the summary of the amendment is not complete and is qualified by the full text of the exhibit. The filing also indicates that the report was intended to satisfy written communications requirements under Rule 425 of the Securities Act.